TrialPath
COPD · Austin

COPD clinical trials in Austin

7 recruiting chronic obstructive pulmonary disease studies within range of Austin. Click any trial for full eligibility criteria and contact info.

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

NCT05919511 · cGVHD
Recruiting

The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

Phase—
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 36 more
SponsorIncyte Corporation
▾Tap for details
Apply

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

Recruiting

This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.

PhasePhase 3
TypeInterventional
Age40 Years – 80 Years
WhereBirmingham, Alabama, United States + 313 more
SponsorSanofi
▾Tap for details
Apply

Freedom-1 Study for Chronic Knee Pain

NCT03877653 · Osteoarthritic Knee Pain
Recruiting

To demonstrate the potential benefits and risk of active sub-threshold stimulation in the treatment of chronic knee pain as compared to subjects that did not have active stimulation. Improvement will be assessed in relation to the clinical outcome measures of pain, with primary endpoint; Pain relief rate as measured by the number of subjects with greater or equal to a 50% decrease in pain on the visual analog scale, comparing baseline to the 1-month follow-up.

PhaseNA
TypeInterventional
Age18 Years
WherePlacentia, California, United States + 12 more
SponsorCuronix LLC
▾Tap for details
Apply

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Recruiting

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

PhasePhase 3
TypeInterventional
Age40 Years – 80 Years
WhereAthens, Alabama, United States + 921 more
SponsorAstraZeneca
▾Tap for details
Apply

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214 · Pulmonary Disease, Chronic Obstructive
Recruiting

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

PhasePhase 3
TypeInterventional
Age40 Years – 80 Years
WhereSheffield, Alabama, United States + 192 more
SponsorGlaxoSmithKline
▾Tap for details
Apply

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774 · Chronic Graft-versus-host-disease
Recruiting

This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).

PhasePhase 3
TypeInterventional
Age12 Years
WhereBirmingham, Alabama, United States + 132 more
SponsorIncyte Corporation
▾Tap for details
Apply

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

NCT06619561 · Chronic Graft-Versus-Host Disease (cGVHD)
Recruiting

The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.

PhasePhase 2
TypeInterventional
Age18 Years
WhereDuarte, California, United States + 25 more
SponsorDeciphera Pharmaceuticals, LLC
▾Tap for details
Apply